FLC
NKTR icon

Fifth Lane Capital’s Nektar Therapeutics NKTR Stock Holding History

Fifth Lane Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$863K Buy
+12,000
New +$683K 1.05% 19
2025
Q4 		– Sell
-4,500
Closed -$256K – 140
2025
Q3 		$256K Buy
+4,500
New +$149K 0.26% 63

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fifth Lane Capital's NKTR Position: Q1 2026 in Review

Fifth Lane Capital opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 12,000 shares worth $863K. The stake represents 1.05% of the portfolio and ranks #19 among its holdings. This is a return to the name: Fifth Lane Capital previously reported a position in NKTR as recently as Q3 2025.

Fifth Lane Capital first reported a position in NKTR in Q3 2025 and has held it in 2 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Fifth Lane Capital held 12,000 shares of Nektar Therapeutics worth $863K as of Q1 2026.
  • Nektar Therapeutics was a new Fifth Lane Capital position in Q1 2026.
  • Nektar Therapeutics made up 1.05% of Fifth Lane Capital's portfolio in Q1 2026, its #19 holding.
  • Fifth Lane Capital first reported a position in Nektar Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Fifth Lane Capital's 13F filing for Q1 2026, filed 15 May 2026.